{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["43(36)"],"submitter":["Hutchings M"],"pubmed_abstract":["<h4>Purpose</h4>An unmet need remains for more effective therapies for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), especially high-grade B-cell lymphoma (HGBCL). We present the primary analysis of a phase Ib/II study (ClinicalTrials.gov identifier: NCT03533283) investigating efficacy and safety of glofitamab plus polatuzumab vedotin (Glofit-Pola) in patients with R/R LBCL, including HGBCL and those who received previous chimeric antigen receptor (CAR) T-cell therapy.<h4>Methods</h4>Patients received 1,000 mg obinutuzumab on Cycle (C)1 Day (D)1 (once daily). Polatuzumab vedotin (1.8 mg/kg) was given on C1D2 and D1 of C2-6 (21-day cycles; once daily). Glofitamab was given as step-up doses in C1 (D8, 2.5 mg; D15, 10 mg) followed by 30 mg on D1 of C2-12 (21-day cycles; once daily)."],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["3788-3798"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12711264"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial."],"pmcid":["PMC12711264"],"pubmed_authors":["Cordoba R","Avigdor A","Skarbnik A","Sellam G","Li D","Dominguez AR","Tandon M","Hutchings M","Larsen TS","Jorgensen JM","Corradini P","Gritti G","Terol MJ","Sureda A","Pinto A","Bottos A","Relf J","Bosch F","Zinzani PL","Leung W"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.","description":"<h4>Purpose</h4>An unmet need remains for more effective therapies for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), especially high-grade B-cell lymphoma (HGBCL). We present the primary analysis of a phase Ib/II study (ClinicalTrials.gov identifier: NCT03533283) investigating efficacy and safety of glofitamab plus polatuzumab vedotin (Glofit-Pola) in patients with R/R LBCL, including HGBCL and those who received previous chimeric antigen receptor (CAR) T-cell therapy.<h4>Methods</h4>Patients received 1,000 mg obinutuzumab on Cycle (C)1 Day (D)1 (once daily). Polatuzumab vedotin (1.8 mg/kg) was given on C1D2 and D1 of C2-6 (21-day cycles; once daily). Glofitamab was given as step-up doses in C1 (D8, 2.5 mg; D15, 10 mg) followed by 30 mg on D1 of C2-12 (21-day cycles; once daily).","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-15T14:29:44.594Z","creation":"2026-07-06T03:08:56.508Z"},"accession":"S-EPMC12711264","cross_references":{"pubmed":["41115257"],"doi":["10.1200/JCO-25-00992"]}}